Shawnte M. Mitchell Joins Olema Oncology as Chief Legal Officer

Author: Logan Wright Updated: 02-18-2025 07:07 AM

Shawnte M. Mitchell's New Role at Olema Oncology

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering biopharmaceutical firm focused on targeting therapies for breast cancer, is excited to announce a significant addition to its executive team: Shawnte M. Mitchell, J.D., has been appointed as the new Chief Legal Officer and Corporate Secretary.

Welcoming a Seasoned Professional

Shawnte brings to Olema 20 years of experience in the healthcare and life sciences sectors, making her an invaluable asset as the company progresses with its innovative clinical programs.

“We are thrilled to have Shawnte on board to lead our Legal team,” shared Sean P. Bohen, M.D., Ph.D., the President and CEO of Olema Oncology. He emphasized the importance of her background in regulatory, commercial, and intellectual property matters, particularly as the company advances its late-stage palazestrant programs.

A Proven Track Record

Before joining Olema, Ms. Mitchell was Chief Legal Officer at Genomatica, where she managed extensive business transformation efforts and oversaw critical compliance initiatives. Her previous role at Zogenix as Executive Vice President, General Counsel, and Corporate Secretary further solidified her expertise in corporate governance, compliance, and operational strategies.

Additionally, she has held significant leadership positions at Aptevo Therapeutics, where she was responsible for corporate affairs and compliance. Ms. Mitchell is also actively involved in community service as a board member of Life Science Cares Bay Area.

Key Insights from Ms. Mitchell

Expressing her enthusiasm, Ms. Mitchell stated, “I am thrilled to join Olema during such pivotal times as the company aims to provide new treatment options for breast cancer patients.” Her eagerness to contribute to Olema's growth and development of cutting-edge therapies reflects her commitment to improving patient outcomes.

About Olema Oncology

Olema Oncology is at the forefront of transforming breast cancer treatment. Committed to excellence, the company focuses on developing novel treatments, including its lead candidate, palazestrant (OP-1250). This oral medication is currently in Phase 3 clinical trials and aims to enhance patient care in endocrine-driven cancers.

Located in San Francisco with facilities in Cambridge, Massachusetts, Olema is dedicated to pushing the boundaries of cancer therapy through innovation and research.

Contact Information

For media inquiries, please contact: Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
Email: media@olema.com

Frequently Asked Questions

What are Shawnte M. Mitchell's qualifications?

Shawnte M. Mitchell holds a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School, bringing over 20 years of industry experience.

What role will Shawnte M. Mitchell play at Olema Oncology?

Shawnte will serve as Chief Legal Officer and Corporate Secretary, overseeing legal functions and supporting corporate governance as the company develops its clinical programs.

What is Olema Oncology's primary focus?

Olema Oncology is dedicated to developing targeted therapies for breast cancer, particularly focusing on novel treatments like palazestrant for endocrine-driven cancer.

Where is Olema Oncology headquartered?

Olema Oncology is headquartered in San Francisco, with additional operations in Cambridge, Massachusetts.

How can I contact Olema for media inquiries?

For media inquiries, please contact Courtney O’Konek at media@olema.com.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.